Published in Biochem J on April 15, 1996
Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A (2002) 1.49
Mass spectrometric and capillary electrophoretic investigation of the enzymatic degradation of heparin-like glycosaminoglycans. Proc Natl Acad Sci U S A (1998) 1.22
Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci U S A (2003) 1.04
Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia (2005) 0.93
Heparin/heparan sulfate N-sulfamidase from Flavobacterium heparinum: structural and biochemical investigation of catalytic nitrogen-sulfur bond cleavage. J Biol Chem (2009) 0.93
Heparin/heparan sulfate 6-O-sulfatase from Flavobacterium heparinum: integrated structural and biochemical investigation of enzyme active site and substrate specificity. J Biol Chem (2009) 0.90
High yield, purity and activity of soluble recombinant Bacteroides thetaiotaomicron GST-heparinase I from Escherichia coli. Arch Biochem Biophys (2007) 0.78
Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination. Anal Chem (2011) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 55.34
Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res (1991) 9.56
Purification and properties of bacterial chondroitinases and chondrosulfatases. J Biol Chem (1968) 5.66
Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev (1991) 3.93
Heparin. N Engl J Med (1991) 3.66
The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. J Biol Chem (1992) 2.85
Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol (1995) 2.21
Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem (1993) 2.07
Polysaccharide lyases. Appl Biochem Biotechnol (1986) 1.81
One-dimensional gel electrophoresis. Methods Enzymol (1990) 1.66
Analysis of glycoprotein-associated oligosaccharides. Annu Rev Biochem (1993) 1.60
Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem (1984) 1.56
Drug-related deaths among medical inpatients. JAMA (1977) 1.53
Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan. Proc Natl Acad Sci U S A (1987) 1.49
Substrate specificity of the heparin lyases from Flavobacterium heparinum. Arch Biochem Biophys (1993) 1.47
Sequential degradation of heparin in Flavobacterium heparinum. Purification and properties of five enzymes involved in heparin degradation. J Biol Chem (1973) 1.44
Purification and characterization of heparinase from Flavobacterium heparinum. J Biol Chem (1985) 1.43
Mapping and quantification of the major oligosaccharide components of heparin. Biochem J (1988) 1.38
Utility of non-covalent complexes in the matrix-assisted laser desorption ionization mass spectrometry of heparin-derived oligosaccharides. Carbohydr Res (1995) 1.29
Mass spectrometric molecular-weight determination of highly acidic compounds of biological significance via their complexes with basic polypeptides. Proc Natl Acad Sci U S A (1994) 1.26
Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity. J Biol Chem (1990) 1.26
The coordinated regulation of heparan sulfate, syndecans and cell behavior. Curr Opin Cell Biol (1993) 1.24
Isolation and characterization of human heparin. Biochemistry (1992) 1.21
Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor. Biochem J (1992) 1.20
Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. J Biol Chem (1994) 1.20
Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A (1994) 1.19
Heparinase production by Flavobacterium heparinum. Appl Environ Microbiol (1981) 1.15
Cloning and expression of heparinase I gene from Flavobacterium heparinum. Proc Natl Acad Sci U S A (1993) 1.14
Detailed structural analysis of a novel, specific O-linked glycan from the prokaryote Flavobacterium meningosepticum. J Biol Chem (1995) 1.12
Study of structurally defined oligosaccharide substrates of heparin and heparan monosulfate lyases. Carbohydr Res (1989) 1.08
Novel, specific O-glycosylation of secreted Flavobacterium meningosepticum proteins. Asp-Ser and Asp-Thr-Thr consensus sites. J Biol Chem (1995) 1.08
Mode of action of heparin lyase on heparin. Biochim Biophys Acta (1982) 1.07
Regulation of vertebrate left-right asymmetries by extracellular matrix. Nature (1992) 1.03
An enzymatic system for removing heparin in extracorporeal therapy. Science (1982) 0.99
On the structure of heparitin sulfates. Analyses of the products formed from heparitin sulfates by two heparitinases and a heparinase from Flavobacterium heparinum. Biochim Biophys Acta (1976) 0.94
Heparan sulfate proteoglycans are required for mesoderm formation in Xenopus embryos. Development (1994) 0.93
Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain. J Biol Chem (1996) 0.88
Immobilized heparin lyase system for blood deheparinization. Methods Enzymol (1988) 0.88
Biosynthesis of heparin and heparan sulfate. Ann N Y Acad Sci (1989) 0.87
Heparinase in the activated clotting time assay: monitoring heparin-independent alterations in coagulation function. Anesth Analg (1992) 0.84
Heparinase I from Flavobacterium heparinum: the role of the cysteine residue in catalysis as probed by chemical modification and site-directed mutagenesis. Biochemistry (1995) 0.84
Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity. J Vasc Surg (1984) 0.83
Purification of heparinase and heparitinase by affinity chromatography on glycosaminoglycan-bound AH-Sepharose 4B. Carbohydr Res (1981) 0.79
Immuno-affinity purification of heparinase. Int J Biochem (1985) 0.77
Heparin pharmacokinetics during hemodialysis. Ther Drug Monit (1989) 0.76
Bioreactor based on suspended particles of immobilized enzyme. Ann Biomed Eng (1993) 0.76
Tools to cleave glycoproteins. Trends Biotechnol (1994) 0.76
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Functional arteries grown in vitro. Science (1999) 6.08
Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J (2010) 4.72
Large porous particles for pulmonary drug delivery. Science (1997) 3.35
New challenges in biomaterials. Science (1994) 2.85
Polymers for the sustained release of proteins and other macromolecules. Nature (1976) 2.81
Stimulation of neurite outgrowth using an electrically conducting polymer. Proc Natl Acad Sci U S A (1997) 2.74
Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 2.73
Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res (1991) 2.70
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Aliment Pharmacol Ther (2012) 2.67
Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi-interpenetrating networks. J Biomed Mater Res (2000) 2.67
Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res (2000) 2.64
Tissue engineering: the design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet (1999) 2.62
Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science (1983) 2.47
Biodegradable polymer scaffolds for tissue engineering. Biotechnology (N Y) (1994) 2.47
A controlled-release microchip. Nature (1999) 2.39
Thermophilic anaerobic digestion of solid waste for fuel gas production. Biotechnol Bioeng (1975) 2.28
Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci U S A (1993) 2.27
Novel approach to fabricate porous sponges of poly(D,L-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials (1996) 2.27
Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract (2011) 2.25
Enzymatic degradation of glycosaminoglycans. Crit Rev Biochem Mol Biol (1995) 2.21
Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc Natl Acad Sci U S A (1991) 2.19
Bioreactor cultivation conditions modulate the composition and mechanical properties of tissue-engineered cartilage. J Orthop Res (1999) 2.19
Microbial utilization of methanol. Adv Appl Microbiol (1972) 2.17
Lipid-based nanotherapeutics for siRNA delivery. J Intern Med (2010) 2.15
Formulation and physical characterization of large porous particles for inhalation. Pharm Res (1999) 2.10
Ultrasound-mediated transdermal protein delivery. Science (1995) 2.07
Dynamic cell seeding of polymer scaffolds for cartilage tissue engineering. Biotechnol Prog (1998) 2.03
Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J Am Chem Soc (2001) 2.02
Controlled release of dopamine from a polymeric brain implant: in vivo characterization. Ann Neurol (1989) 2.01
Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol Bioeng (1999) 2.00
Transdermal photopolymerization for minimally invasive implantation. Proc Natl Acad Sci U S A (1999) 1.99
Isolation and characterization of a thermotolerant methanol-utilizing yeast. Appl Microbiol (1973) 1.95
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric (2013) 1.94
Tissue engineering of functional cardiac muscle: molecular, structural, and electrophysiological studies. Am J Physiol Heart Circ Physiol (2001) 1.90
Neocartilage formation in vitro and in vivo using cells cultured on synthetic biodegradable polymers. J Biomed Mater Res (1993) 1.88
Maternal and newborn vitamin D status and its impact on food allergy development in the German LINA cohort study. Allergy (2012) 1.88
Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci (1980) 1.86
Sequencing complex polysaccharides. Science (1999) 1.85
In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials (2000) 1.85
Malaria epidemiology in the province of Moyen Ogoov, Gabon. Trop Med Parasitol (1995) 1.85
Morphologic and mechanical characteristics of engineered bovine arteries. J Vasc Surg (2001) 1.84
Polysaccharide lyases. Appl Biochem Biotechnol (1986) 1.81
Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol (1992) 1.79
Isolations of a cartilage factor that inhibits tumor neovascularization. Science (1976) 1.79
Identification of an inhibitor of neovascularization from cartilage. Science (1990) 1.78
Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension (2000) 1.77
Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer human bone. Biomaterials (1996) 1.76
Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg (1998) 1.76
Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A (2001) 1.76
Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol (2000) 1.75
Genetic evidence that heparin-like glycosaminoglycans are involved in wingless signaling. Development (1997) 1.74
Cytoskeletal filament assembly and the control of cell spreading and function by extracellular matrix. J Cell Sci (1995) 1.71
Heparan sulfate mediates bFGF transport through basement membrane by diffusion with rapid reversible binding. J Biol Chem (1999) 1.70
Recruitment of Mycobacterium tuberculosis specific CD4+ T cells to the site of infection for diagnosis of active tuberculosis. J Intern Med (2008) 1.68
Severe nephrotic syndrome in a patient with Schönlein-Henoch purpura: complete remission after cyclosporin A. Nephrol Dial Transplant (1997) 1.60
The stimulation of DNA synthesis and cell division in chondrocytes and 3T3 cells by a growth factor isolated from cartilage. Exp Cell Res (1977) 1.60
A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci (1997) 1.58
Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials (1993) 1.57
Transdermal monitoring of glucose and other analytes using ultrasound. Nat Med (2000) 1.57
Tissue engineering of cartilage in space. Proc Natl Acad Sci U S A (1997) 1.57
Selective cell transplantation using bioabsorbable artificial polymers as matrices. J Pediatr Surg (1988) 1.55
Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis (1994) 1.53
Transdermal photopolymerization of poly(ethylene oxide)-based injectable hydrogels for tissue-engineered cartilage. Plast Reconstr Surg (1999) 1.52
Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J Biomed Mater Res (1997) 1.51
[MRI with supermagnetic iron particles versus double-spiral CT in identification of malignant liver lesions]. Rofo (1998) 1.51
Cell surface glypicans are low-affinity endostatin receptors. Mol Cell (2001) 1.51
Fallopian tube torsion: laparoscopic evaluation and treatment of a rare gynecological entity. J Am Board Fam Pract (2001) 1.49
Controlled and modulated release of basic fibroblast growth factor. Biomaterials (1991) 1.48
Collagen in tissue-engineered cartilage: types, structure, and crosslinks. J Cell Biochem (1998) 1.47
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-unsubstituted glucosamine residues. J Biol Chem (1999) 1.45
High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg (1996) 1.45
Synthetic polymers seeded with chondrocytes provide a template for new cartilage formation. Plast Reconstr Surg (1991) 1.44
Preparation of poly(glycolic acid) bonded fiber structures for cell attachment and transplantation. J Biomed Mater Res (1993) 1.44
Bacterial inactivation by using near- and supercritical carbon dioxide. Proc Natl Acad Sci U S A (1999) 1.43
Purification and characterization of heparinase from Flavobacterium heparinum. J Biol Chem (1985) 1.43
Transdermal drug delivery using low-frequency sonophoresis. Pharm Res (1996) 1.42
Six3 overexpression initiates the formation of ectopic retina. Genes Dev (1999) 1.42
Chondrogenesis in a cell-polymer-bioreactor system. Exp Cell Res (1998) 1.42
Protein stability in controlled-release systems. Nat Biotechnol (2000) 1.41
Silk based biomaterials to heal critical sized femur defects. Bone (2006) 1.40
Responsive polymeric delivery systems. Adv Drug Deliv Rev (2001) 1.40
Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc Natl Acad Sci U S A (1989) 1.39
Fabrication of degradable polymer scaffolds to direct the integration and differentiation of retinal progenitors. Biomaterials (2005) 1.38
Glucocorticoids prolong rat sciatic nerve blockade in vivo from bupivacaine microspheres. Anesthesiology (1996) 1.37
Growth of Enterobacter aerogenes in a chemostat with double nutrient limitations. Appl Environ Microbiol (1976) 1.36
Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol (1985) (1998) 1.36
Electrically conducting polymers can noninvasively control the shape and growth of mammalian cells. Proc Natl Acad Sci U S A (1994) 1.33
Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res (1985) 1.33
Medaka eyeless is the key factor linking retinal determination and eye growth. Development (2001) 1.32
Tissue engineering: current state and perspectives. Appl Microbiol Biotechnol (2004) 1.32
Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine (1994) 1.31
Biomimetic approach to cardiac tissue engineering. Philos Trans R Soc Lond B Biol Sci (2007) 1.31